Difference between revisions of "Team:NCTU Formosa"

Line 195: Line 195:
 
      <div class="photocontent1"><h2>Who are we</h2>
 
      <div class="photocontent1"><h2>Who are we</h2>
 
         NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO     
 
         NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO     
−
         devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic   
+
         devoted to developing detection technology by uti-  lizing antibodies. In 2015, We cooperated with iGEM with Synthetic   
 
         Biology to develop a brand new detection platform. </div>
 
         Biology to develop a brand new detection platform. </div>
 
    </div>
 
    </div>
Line 203: Line 203:
 
      <div class="photocontent2"><h2>What's new</h2>
 
      <div class="photocontent2"><h2>What's new</h2>
 
  APOllO E.Cotector:<br>   
 
  APOllO E.Cotector:<br>   
−
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
+
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen -antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
 
      </div> </div>
 
      </div> </div>
 
              
 
              

Revision as of 13:47, 18 September 2015

The only thing we can detect is everything.

Who are we

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by uti- lizing antibodies. In 2015, We cooperated with iGEM with Synthetic Biology to develop a brand new detection platform.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen -antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.